Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 6, 2009, Pages 671-678

  van Dorp, Suzanne ^a,b   Pietersma, Floor ^b   Wölfl, Matthias ^c   Verdonck, Leo F ^a   Petersen, Eefke J ^a   Lokhorst, Henk M ^a   Martens, Edwin ^b   Theobald, Matthias ^a   van Baarle, Debbie ^b   Meijer, Ellen ^a   Kuball, Jürgen ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

GVHD; Host B cells; RICT

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; LOMUSTINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PATIENT SELECTION; PREMEDICATION; RETROSPECTIVE STUDIES; SAMPLE SIZE; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 67349172120     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.02.005     Document Type: Article

References (24)

1. Appelbaum F.R. Haematopoietic cell transplantation as immunotherapy. Nature 411 (2001) 385-389
2. Lee S.J. New approaches for preventing and treating chronic graft-versus-host disease. Blood 105 (2005) 4200-4206
3. Rouquette-Gally A.M., Boyeldieu D., Prost A.C., and Gluckman E. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation 46 (1988) 238-240
4. Sun Y., Tawara I., Toubai T., and Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res 150 (2007) 197-214
5. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 9 (2003) 505-511
6. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 104 (2004) 2603-2606
7. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108 (2006) 756-762
8. Zaja F., Bacigalupo A., Patriarca F., et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 40 (2007) 273-277
9. Kebriaei P., Saliba R.M., Ma C., et al. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 38 (2006) 203-209
10. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
11. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11 (2005) 945-956
12. Lee S.J., Vogelsang G., and Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 9 (2003) 215-233
13. Berinstein N.L., Grillo-Lopez A.J., White C.A., et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9 (1998) 995-1001
14. Cartron G., Blasco H., Paintaud G., Watier H., and Le G.C. Pharmacokinetics of rituximab and its clinical use: thought for the best use?. Crit Rev Oncol Hematol 62 (2007) 43-52
15. Anolik J.H., Friedberg J.W., Zheng B., et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 122 (2007) 139-145
16. Antin J.H. Reduced-intensity stem cell transplantation: "... whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2. Hematology Am Soc Hematol Educ Program 2007 (2007) 47-54
17. Cutler C., Giri S., Jeyapalan S., et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 19 (2001) 3685-3691
18. Wynn T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117 (2007) 524-529
19. Schultz K.R., Paquet J., Bader S., and HayGlass K.T. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 16 (1995) 289-295
20. Matte C.C., Liu J., Cormier J., et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 10 (2004) 987-992
21. Rowe V., Banovic T., MacDonald K.P., et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 108 (2006) 2485-2492
22. Nguyen V.H., Shashidhar S., Chang D.S., et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 111 (2008) 945-953
23. Zhao D., Zhang C., Yi T., et al. In vivo activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic GVHD. Blood 112 (2008) 2129-2138
24. Yi T., Zhao D., Lin C.L., et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft versus host disease. Blood 112 (2008) 2101-2110